Cargando…

Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review

β-thalassemia is characterized by the faulty generation of hemoglobin resulting in an elevated α/β globin ratio; this led to several patients needing red blood cell (RBC) transfusions for the rest of their lives. Luspatercept is an erythroid maturation test for treating various types of anemia, incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dighriri, Ibrahim M, Alrabghi, Khawlah K, Sulaiman, Dilveen M, Alruwaili, Abdulrahman M, Alanazi, Nader S, Al-Sadiq, Al-maha A, Hadadi, ‌‏Amal M, Sahli, Bushra Y, Qasem, Basil A, Alotaibi, Manal T, Asiri, Taif T, Majrashi, Salman M, Alotibia, Noura T, Alhamyani, Afnan T, Alharbi, Amjad A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756914/ https://www.ncbi.nlm.nih.gov/pubmed/36540460 http://dx.doi.org/10.7759/cureus.31570

Ejemplares similares

An Overview of the Current State and Perspectives of Pharmacy Robot and Medication Dispensing Technology
por: Alahmari, Asmaa R, et al.
Publicado: (2022)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
por: Jackson, Nicholas, et al.
Publicado: (2020)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
por: Delaporta, P., et al.
Publicado: (2022)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
por: Viprakasit, V., et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia
por: Chen, Nianhang, et al.
Publicado: (2020)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

P1508: LUSPATERCEPT REDUCES THE BURDEN OF RED BLOOD CELL TRANSFUSION IN PATIENTS WITH BETA -THALASSEMIA AND COMORBIDITIES: THE EXPERIENCE OF A SINGLE THALASSEMIA AND SICKLE CELL UNIT IN A UNIVERSITY HOSPITAL
por: Delicou, S., et al.
Publicado: (2022)

P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL
por: Coates, Thomas D., et al.
Publicado: (2023)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

S101: COMBINATION OF A LUSPATERCEPT-LIKE DRUG (RAP-GRL) AND TMPRSS6-ASO IS SUPERIOR TO EITHER DRUG ALONE FOR CORRECTING β-THALASSEMIA
por: Guerra, A., et al.
Publicado: (2022)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

5610224 THE USE OF LUSPATERCEPT IN PATIENTS WITH β -THALASSAEMIA AND MULTIPLE SYSTEMIC COMPLICATIONS INCREASES HEMOGLOBIN LEVEL, DECREASES TRANSFUSION BURDEN, AND IS UNAFFECTED BY COMPLICATIONS. SINGLE THALASSEMIA AND SICKLE CELL DEPARTEMENT’S EXPERIENCE.
por: Manganas, K.M., et al.
Publicado: (2023)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
por: Garcia-Manero, Guillermo, et al.
Publicado: (2022)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA-THALASSEMIA
por: Viprakasit, Vip, et al.
Publicado: (2023)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
por: Khan, Shamis, et al.
Publicado: (2022)

Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes
por: Marchand, Alexandre, et al.
Publicado: (2022)

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
por: Germing, Ulrich, et al.
Publicado: (2023)

Perceived stress and monetary burden among thalassemia patients and their caregivers
por: Hisam, Aliya, et al.
Publicado: (2018)

Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis
por: Yun, Nicole K., et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020)

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
por: Wobus, Manja, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Association of serum asymmetric dimethyl-arginine and troponin I levels as a risk of myocardial infarction in thalassemia
por: Helmi, Nawal, et al.
Publicado: (2018)

Osteoporosis in Iraqi patients with thalassemia
por: AL Jadir, Salim M, et al.
Publicado: (2012)

β-Thalassemia Mutations among Transfusion-Dependent Thalassemia Major Patients in Northern Iraq
por: Al-Allawi, Nasir A. S., et al.
Publicado: (2010)

Prevalence, Patterns, and Associated Factors for Musculoskeletal Disorders Among the Healthcare Workers of Northern Saudi Arabia: A Multicenter Cross-Sectional Study
por: Alruwaili, Sager Holyl, et al.
Publicado: (2023)

Protein C and S levels in patients with Thalassemia intermedia
por: Mohammed, Nawsherwan Sadiq
Publicado: (2022)

Neonatal hemolytic anemia does not always indicate thalassemia: a case report
por: Al-Harazi, Arwa A., et al.
Publicado: (2017)

Prevalence and Associated Risk Factors of Dry Eye Disease Among Children and Adults in Saudi Arabia: A Cross-Sectional Study
por: Alrabghi, Dana A, et al.
Publicado: (2023)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g6f1fb7tv2a2jc8ptm2jffr5ek